Since PD-L1 testing is required for starting first-line treatment with atezolizumab and pembrolizumab in urothelial carcinoma, it is important to elucidate what assay and specimen type are most representative for prediction of therapeutic response. This evidence concerns the gene CD274 and urothelial carcinoma.